Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has entered into an exclusive supply and distribution agreement with AstraZeneca in the U.S. to distribute the authorized generic version of AstraZeneca's Accolate (zafirlukast). Par began shipping 10 mg and 20 mg strengths of zafirlukast tablets on Friday, November 19, 2010. According to IMS Health data, annual sales in the U.S. for Accolate are approximately $50 million.
SOURCE Par Pharmaceutical Companies, Inc.
